News

Neurimmune today announced that the company joined the ACCESS-AD consortium, a new European initiative to accelerate the implementation of scientific innovations for Alzheimer’s disease (AD) management in real-world health systems.

AL-S Pharma will present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15, 2026.

AL-S Pharma today presented its Phase 2 clinical study results on AP-101 at the 36th International Symposium on ALS/MND in San Diego.

Neurimmune today announced that it has expanded on its ATTR-CM collaboration with Alexion, AstraZeneca Rare Disease by entering into a collaboration and license agreement to develop NI009 for the treatment of AL amyloidosis.

Neurimmune today announced it has initiated a Phase 2 follow-on study to evaluate the pharmacodynamics and safety of cliramitug for transthyretin amyloid cardiomyopathy in patients who were previously enrolled in the proof-of-concept study NI006-101.

AL-S Pharma announced today that it has appointed Angela Genge, MD, Professor of Neurology at McGill University in Montreal, as Chief Medical Officer.

AL-S Pharma today announced positive topline results from the Phase 2 clinical study evaluating AP-101, a potential first-in-class, disease-modifying treatment for amyotrophic lateral sclerosis (ALS).

Neurimmune today announced that new data from the open-label extension of the Phase I trial of cliramitug (formerly NI006, ALXN2220) for the treatment of ATTR-CM will be presented at the ESC Congress 2025 in Madrid.

Neurimmune and AICURA Medical GmbH today announced a strategic collaboration to harness the latest breakthroughs in artificial intelligence (AI) for the development of therapeutics for the treatment of Alzheimer’s disease.